Hormuz crisis squeezes India's pharma supply chains

TL;DR

Hormuz Crisis Bottlenecks: Strait of Hormuz disruptions are slowing pharma supply chains, hitting India's imports from China and exports to West Asia.
6% Exports Risked: About 6 per cent of India's pharmaceutical exports face immediate issues due to shipments through the strait to UAE, Saudi Arabia and others.
Buffers Absorb Shock: Three-to-six-month inventory cushions limit near-term pain, though costs rise 2-5 per cent from energy and freight hikes.

The story at a glance

The Strait of Hormuz crisis is disrupting pharmaceutical shipments, delaying active pharmaceutical ingredients (APIs) and key starting materials (KSMs) from China to India while complicating exports to the Middle East and North Africa (MENA). India's industry faces higher costs and logistical hurdles, though inventory buffers offer short-term relief. Brokerage JM Financial and industry leaders like Pharmexcil's Namit Joshi highlight contained impacts for now. This emerges over 45 days into the crisis amid stalled diplomacy and Chinese vessel constraints.

Key points

India's pharma imports $4.35 billion worth of APIs, bulk drugs and intermediates yearly, with three-fourths from China, including 70 per cent of vaccine raw materials and 74 per cent of APIs.
Energy and power costs up 20-30 per cent; petrochemical solvents and intermediates see price hikes, with global suppliers like BASF raising excipient and API prices up to 20 per cent.
Air freight rates jumped nearly 400 per cent post-disruption; rerouting via Cape of Good Hope adds up to 15 days, risking temperature-sensitive drugs.
Exports to MENA could drop 10-20 per cent from longer transit, higher freight and delays; India supplies 40 per cent of Iran's generic medicines.
Large firms like Sun Pharma and Dr. Reddy’s Laboratories rely on three-to-six-month buffers; mid-sized players face working capital strain.
Overall cost inflation estimated at 2-5 per cent near-term from crude-linked inputs, energy and freight.

Details and context

Disruptions stem from constraints on Chinese vessels in the Persian Gulf and Gulf of Oman, slowing cargo to Indian ports like Mundra and JNPT. Exporters invoke force majeure or war clauses in contracts to manage delays.

Cold-chain logistics for biologics and vaccines are vulnerable to extended timelines. Clinical trials may see delayed cost rises.

India built inventory post-pandemic, insulating it somewhat compared to global peers more exposed to real-time Chinese flows. Prolonged issues could pressure receivables from Gulf markets, where Dubai serves as a key redistribution hub.

Key quotes

“The biggest impact is crude -- rising petrochemical costs are increasing conversion costs. The supply chain is functioning but with delays,” said Namit Joshi, chairman of Pharmexcil.

“A large part of this trade is routed via Dubai... Any tightening of shipping conditions means cargo... now faces delays, rerouting and longer transit cycles,” said an industry executive.

Why it matters

Global pharma supply chains, already fragile post-pandemic, now face compounded risks from geopolitical flashpoints like Hormuz, potentially raising medicine prices worldwide. For Indian firms and patients in Africa, Southeast Asia and the Middle East reliant on its generics and vaccines, delays mean shortages or costlier treatments. Watch if disruptions exceed two more months, as buffers deplete and mid-sized exporters signal broader strain.

What changed

Vessels previously passed freely through the Strait of Hormuz; now Chinese ships face delays and safe passage limits in the Persian Gulf and Gulf of Oman. Cargo flows to India have slowed, with Europe-India routes rerouted via Cape of Good Hope extending timelines to 40-45 days. This shift began over 45 days ago amid the ongoing crisis.

FAQ

Q: Why are pharma imports from China delayed?

A: Constraints on Chinese vessels in the Persian Gulf and Gulf of Oman slow APIs and KSMs to ports like Mundra and JNPT. Rerouting adds up to 15 days via Cape of Good Hope, with air freight rates up nearly 400 per cent as an unscalable alternative.

Q: Which exports are most at risk?

A: Shipments to West Asia including UAE, Saudi Arabia, Oman, Iraq and Iran, totaling about 6 per cent of India's pharma exports routed via Strait of Hormuz. MENA volumes could fall 10-20 per cent from longer transits and higher costs.

Q: How are cost increases affecting the sector?

A: Energy costs rose 20-30 per cent, driving 2-5 per cent inflation from crude-linked inputs, freight and power. BASF hiked excipient and API prices up to 20 per cent; India's China-dependent inputs amplify this.

Q: What protects India short-term?

A: Post-pandemic buffers of three to six months cover fermentation-based antibiotics, vitamins and intermediates. Large makers like Sun Pharma use domestic API capacity, though mid-sized firms face capital pressures.